1832 related articles for article (PubMed ID: 12646921)
21. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.
Watkins BA; Buge S; Aldrich K; Davis AE; Robinson J; Reitz MS; Robert-Guroff M
J Virol; 1996 Dec; 70(12):8431-7. PubMed ID: 8970964
[TBL] [Abstract][Full Text] [Related]
22. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction.
Huang X; Jin W; Hu K; Luo S; Du T; Griffin GE; Shattock RJ; Hu Q
Virology; 2012 Feb; 423(1):97-106. PubMed ID: 22192629
[TBL] [Abstract][Full Text] [Related]
23. Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.
Drummer HE; Hill MK; Maerz AL; Wood S; Ramsland PA; Mak J; Poumbourios P
PLoS Pathog; 2013; 9(4):e1003218. PubMed ID: 23592978
[TBL] [Abstract][Full Text] [Related]
24. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
[TBL] [Abstract][Full Text] [Related]
25. Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.
Hatada M; Yoshimura K; Harada S; Kawanami Y; Shibata J; Matsushita S
J Gen Virol; 2010 May; 91(Pt 5):1335-45. PubMed ID: 20032207
[TBL] [Abstract][Full Text] [Related]
26. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
[TBL] [Abstract][Full Text] [Related]
27. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
28. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.
Wang Q; Shang H; Han X; Zhang Z; Jiang Y; Wang Y; Dai D; Diao Y
Microbiol Immunol; 2008 Apr; 52(4):209-15. PubMed ID: 18426395
[TBL] [Abstract][Full Text] [Related]
29. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
30. Methods for analysis of biologically functional antibodies to the HIV-1 gp120 principal neutralizing domain.
Devash Y; Rusche JR; Nara PL
Biotechnol Ther; 1991; 2(1-2):49-62. PubMed ID: 1845124
[TBL] [Abstract][Full Text] [Related]
31. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
[TBL] [Abstract][Full Text] [Related]
32. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
33. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
[TBL] [Abstract][Full Text] [Related]
35. Genotypic and phenotypic characterization of a neutralization-resistant breakthrough population of HIV-1.
Sirko DA; Ehrlich GD
Virology; 1996 Apr; 218(1):238-42. PubMed ID: 8615028
[TBL] [Abstract][Full Text] [Related]
36. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.
Rong R; Li B; Lynch RM; Haaland RE; Murphy MK; Mulenga J; Allen SA; Pinter A; Shaw GM; Hunter E; Robinson JE; Gnanakaran S; Derdeyn CA
PLoS Pathog; 2009 Sep; 5(9):e1000594. PubMed ID: 19763269
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades.
Zhang MY; Shu Y; Sidorov I; Dimitrov DS
Antiviral Res; 2004 Mar; 61(3):161-4. PubMed ID: 15168796
[TBL] [Abstract][Full Text] [Related]
38. Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence.
Andrabi R; Choudhary AK; Bala M; Kalra R; Prakash SS; Pandey RM; Luthra K
Arch Virol; 2011 Oct; 156(10):1787-94. PubMed ID: 21735212
[TBL] [Abstract][Full Text] [Related]
39. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
[TBL] [Abstract][Full Text] [Related]
40. Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity.
Skrabal K; Saragosti S; Labernardière JL; Barin F; Clavel F; Mammano F
J Virol; 2005 Sep; 79(18):11848-57. PubMed ID: 16140761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
